ABBVIE INC.

ABBV

Delayed - 05/27 04:03:14 pm
150USD	-0.38%

Turn to zoom

Prev.	150.0000
Open	149.5200
High	150.0500
Low	147.7500
Volume	8 403 429

8h ago	The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs...
8h ago	The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs...
8h ago	The Lancet Results from Phase 3 Induction and Maintenance Programs...
1d ago	Insider Sell: Abbvie

	Short Term	Mid-Term	Long Term
Trend	Neutral	Neutral	Bullish
Resistance	162	175	175
Spread/Res.	-8,6%	-15%	-15%
Spread/Supp.	0,97%	29%	9,1%
Support	147	115	136

Sales 2022	59 604 M - -
Net income 2022	17 475 M - -
Net Debt 2022	53 760 M - -
P/E ratio 2022	15,6x
Yield 2022	3,79%

Capitalization	266 B 266 B -
EV / Sales 2022	5,37x
EV / Sales 2023	5,52x
Nbr of Employees	50 000
Free-Float	99,9%

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with...

>> Read more

Sector :

Other Pharmaceuticals

Calendar :

2022-06-01 Presentation

Trading Rating :

Investor Rating :

Sell Buy
Mean consensus	OUTPERFORM
Number of Analysts	25
Last Close Price	150,57 $
Average target price	164,23 $
Spread / Average Target	9,07%